Leadership & Pay ·
Anavex Life Sciences Corp. announced plans to refresh its Board of Directors at the 2026 Annual Meeting by nominating…
AVXLAnavex Life Sciences Corp.
Anavex Life Sciences Corp. announced plans to refresh its Board of Directors at the 2026 Annual Meeting by nominating two new independent directors, Gautam Patel and Dr. Adrian Senderowicz, while not renominating former CEO Christopher Missling and director Dr. Steffen Thomas. The current board urged stockholders to reject a proxy contest filed by PVG Asset Management Corporation and Patrick S. Adams seeking to replace the entire board with nominees who own only 0.35% of outstanding shares. Interim CEO Dr. Terrie Kellmeyer will oversee operations following Missling's termination for cause, which delayed the filing of the company's quarterly report. The company maintains a strong cash runway and no long-term debt while prioritizing its lead candidate blarcamesine for Alzheimer's disease, Rett syndrome, and Fragile X syndrome. Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases.